Manufacturing

Nicholas Saraceno is editor at Pharmaceutical Commerce.

Articles

The Thousand Oaks, Calif., cell therapy manufacturing facility now houses new production suites, updated development labs, and more after expansion.

Fujifilm's Cell Therapy Facility Expansion Completed

Feliza Mirasol is the science editor for 

Manufacturers of five autologous or matched allogenic cell therapy products have selected TrakCel's  IT platform, OCELLOS, to orchestrate the administration of these therapies, which are approved or expected to be approved in 2024.

TrakCel’s OCELLOS Platform Selected to Support Treatment Management of Five Upcoming Cell Therapy Products

The new Institute for Cell Therapy Discovery and Innovation will utilize expertise to develop cell therapies for cancer, autoimmune diseases, and infections.

MD Anderson Launches Cell Therapy Institute

CPC’s MicroCNX ULT Series represents the first aseptic microconnector that can be fitted directly into freeze cassettes for GCT production.

Aseptic Micro-Connector

Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

Videos

Cell and gene therapy experts Fabian Gerlinghaus, Dr. Claudia Zylberberg, and Benjamin McLeod weigh in on hot topics in CGT. 

Buy, Sell, Hold: Cell and Gene Therapy - Part 3

Buy, Sell, Hold: Cell and Gene Therapy - Part 2

Buy, Sell, Hold: Cell and Gene Therapy - Part 1

The two companies are partnering to provide logistics and manufacturing services to biotechnology and pharma companies.

Cryoport and SK pharmteco Partner on Cell and Gene Therapies

Lonza signed a long-term supply agreement to manufacture CASGEVY (exagamglogene autotemcel) for Vertex at its facility in Geleen, the Netherlands, and plans to expand manufacturing to Portsmouth, NH, in the United States.

Lonza and Vertex Enter Commercial Supply Agreement for CASGEVY, the Sickle Cell Disease Gene-Edited Cell Therapy

Patrick Lavery is an Editor for the MJH Life Sciences brands 

. Previously at MJH, he filled the same role for 

The next-generation IRO platform was found to significantly outperform the legacy Prodigy system, showing improvements in cell growth, CAR+ cell yield, and overall efficiency.

Manufacturing, Cell Therapies